Risk factors for vancomycin-resistant Enterococcus colonization in hematologic patients

Vesna Mioljević; Ljiljana Marković-Denić; Ana Vidović; Milica Jovanović; Tanja Tošić; Dragica Tomin

doi:10.2298/1818

Vesna Mioljević Department of Hospital Epidemiology and Hygiene,Clinical Center of Serbia, Belgrade, Serbia
Ljiljana Marković-Denić Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Ana Vidović Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Milica Jovanović Microbiology Department, Clinical Center of Serbia, Belgrade, Serbia
Tanja Tošić Microbiology Department, Clinical Center of Serbia, Belgrade, Serbia
Dragica Tomin Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia

DOI: https://doi.org/10.2298/1818

Keywords: enterococcus faecium, vancomycin, drug resistance, bacterial, hematologic diseases, risk factors,

Abstract

References

Willems RJ, Bonten MJ. Glycopeptide-resistant enterococci: de-ciphering virulence, resistance and epidemicity. Curr Opin In-fect Dis 2007; 20(4): 384−90.

Sujatha S, Praharaj I. Glycopeptide resistance in gram-positive cocci: a review. Interdiscip Perspect Infect Dis 2012; 2012: 781679.

Surveillance report. Antimicrobial resistance surveillance in Europe, 2009. Available from: www.ecdc.europa.eu/en/.../1011_SUR_annual_EARS_Net_2009

Arias C, Murray B. The rise of the Enterococcus: beyond van-comycin resistance. Nat Rev Microbiol 2012; 10(4): 266−78.

Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, anti-microbial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveil-lance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2: S133−45.

Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence and spread of vancomycin resis-tance among enterococci in Europe. Euro Surveill 2008; 13(47). pii: 19046.

ECDC. Antimicrobial resistance surveillance in Europe 2010. Annual report of the European Antimicrobial Resistance Sur-veillance Network (EARS-Net). Available from: http://repositorio.insa.pt/handle/10400.18/702

National Nosocomial Infections Surveillance (NNIS) System Report data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32(8): 470−85.

Achenbach C, Flores E, Farerrell P, Pitrak D,Weber G. Prevalence of risk factors for colonization with vancomicyn-resistant enterococcus among human immunodeficiency virus positive outpatients. Infect Control Hosp Epidemiol 2006; 27(1): 102−4.

Sakka V, Tsiodras S, Galani L, Antoniadou A, Souli M, Galani I, et al. Risk-factors and predictors of mortality in patients colo-nised with vancomycin-resistant enterococci. Clin Microbiol Infect 2008; 14(1): 14−21.

Tacconelli E, Cataldo MA. Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents 2008; 31: 99−106.

Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, et al. SHEA Guideline for Preventing Nosocomial Transmission of Multidrug-Resistant Strains of Staphylococcus aureus and Enterococcus spp. Infect Control Hosp Epidemiol 2003; 24(5); 362−86.

Yoon YK, Lee SE, Lee J, Kim HJ, Kim JY, Park DW, et al. Risk factors for prolonged carriage of vancomycin-resistant Ente-rococcus faecium among patients in intensive care units: a case-control study. J Antimicrob Chemother 2011; 66(8): 1831−8.

CLSI. Performance Standards for Antimicrobial Disk Suscep-tibility Testing; Seventeenth Informational Supplement M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.

CLSI. Performance Standards for Antimicrobial Disk Suscep-tibility Tests; M02-A10. Approved Standard − Tenthth edi-tion. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.

Gambarotto K, Ploy MC, Turlure P, Grélaud C, Martin C, Bordes-soule D, et al. Prevalence of vancomycin-resistant enterococci in fecal samples from hospitalized patients and nonhospita-lized controls in a cattle-rearing area of France. J Clin Micro-biol 2000; 38(2): 620−4.

van den Braak N, Ott A, van Belkum A, Kluytmans JA, Koeleman JG, Spanjaard L, et al. Prevalence and determinants of fecal colonization with vancomycin-resistant Enterococcus in hospitalized patients in The Netherlands. Infect Control Hosp Epidemiol 2000; 21(8): 520−4.

Almyroudis NG, Lesse AJ, Hahn T, Samonis G, Hazamy PA, Wongkittiroch K, et al. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in pa-tients with hematologic malignancies. Infect Control Hosp Epidemiol 2011; 32(5): 490−6.

Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fätkenheuer G, Wisplinghoff H, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistantentero-cocci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 2012; 40(6): 613−9.

Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and in-fection with vancomycin-resistant Enterococcus among pa-tients with cancer. Am J Infect Control 2006; 34(8): 534−6.

Suntharam N, Lankford MG, Trick WE, Peterson LR, Noskin GA. Risk factors for acquisition of vancomycin-resistant enterococci among hematology-oncology patients. Diagn Microbiol Infect Dis 2002; 43(3): 183−8.

Mirović V, Tomanović B, Konstantinović S. The frequency of resis-tance to antibiotics of most frequently isolated bacteria from blood cultures during the period 1997-2002. Vojnosanit Pregl 2004; 61(4): 391−7. (Serbian)

Cheong HJ, Song JY, Eom JS, Kim WJ, Choi SJ, Choi JH, et al. Colonization rate, risk factor for acquisition, and genetic sensity of vancomicyn-resistant enterococci (VRE) isolated from culture of patients in intensive care unit from Korea. Korean J Infect Dis 2002; 34: 276−84.

Metallidis S, Chatzidimitriou M, Tsona A, Bisiklis A, Lazaraki G, Koumentaki E, et al. Vancomicyn-Resistant Enterococci, Colonizing the Intenstinal Tract of Patients in a University Hospital in Greece. Braz J Infect Dis 2006; 10(3): 179−84.

Song JY, Cheong HJ, Jo YM, Choi WS, Noh JY, Heo JY, et al. Vancomicyn-Resistant Enterococci colonization before admi-sion to the intensive care unit: A clinico-epidemiological analysis. Am J Infect Control 2009; 37(9): 734−40.

Padiglione AA, Wolfe R, Grabsch EA, Olden D, Pearson S, Franklin C, et al. Risk Factors for New Detection of Van-comycin-Resistant Enterococci in Acute-Care Hospitals That Employ Strict Infection Control Procedures. Antimocrob Agents Chemother 2003; 47(8): 2492–8.

Carmely Y, Samore MH, Huskins C. The association between antecedent vancomicyn teatment and hospital-acquired vancomicyn-resistent eneterococci; a meta analysis. Arch Intern Med 1999; 159(20): 2461−8.

Ostrovsky BE, Venkataraman L, D'Agata EM, Gold HS, De Girolami, Samore MH. Vancomicyn-resistant enterococci intensive care units: high freguency of stool carrige during a non outbreak period. Arch Intern Med 1999; 159(13): 1467−72.

de Bruin MA, Riley LW. Does vancomycin prescribing intervention affect vancomycin-resistant enterococcus infection and colonization in hospitals? A systematic review. BMC Infect Dis 2007; 7: 24−35.

Stiefel U, Paterson DL, Pultz NJ, Gordon SM, Aron DC, Donskey CJ. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four aca-demic medical centers. Infect Control Hosp Epidemiol 2004; 25(5): 380−3.

Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, at al. NHSN annual update: antimicrobial-resistant pa-thogens associated with healthcare-associated infections: an-nual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Pre-vention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29(11): 996−1011.